Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer.

Publisher: BioMed Central Country of Publication: England NLM ID: 101170544 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7819 (Electronic) Linking ISSN: 14777819 NLM ISO Abbreviation: World J Surg Oncol Subsets: MEDLINE

Original Publication: London : BioMed Central, 2003-

Liver Neoplasms* ; Carcinoma, Hepatocellular*/drug therapy ; Antineoplastic Agents*/adverse effects ; Chemoembolization, Therapeutic*/methods; Humans ; Sorafenib/therapeutic use ; Niacinamide/adverse effects ; Phenylurea Compounds/adverse effects ; Treatment Outcome ; Combined Modality Therapy

Objective: The clinical efficacy and safety of sorafenib in patients with advanced liver cancer (ALC) were evaluated based on transarterial chemoembolization (TACE).
Methods: 92 patients with ALC admitted to our hospital from May 2020 to August 2022 were randomly rolled into a control (Ctrl) group and an observation (Obs) group, with 46 patients in each. Patients in the Ctrl group received TACE treatment, while those in the Obs group received sorafenib molecular targeted therapy (SMTT) on the basis of the treatment strategy in the Ctrl group (400 mg/dose, twice daily, followed by a 4-week follow-up observation). Clinical efficacy, disease control rate (DCR), survival time (ST), immune indicators (CD3+, CD4+, CD4+/CD8+), and adverse reactions (ARs) (including mild fatigue, liver pain, hand-foot syndrome (HFS), diarrhea, and fever) were compared for patients in different groups after different treatments.
Results: the DCR in the Obs group (90%) was greatly higher to that in the Ctrl group (78%), showing an obvious difference (P < 0.05). The median ST in the Obs group was obviously longer and the median disease progression time (DPT) was shorter, exhibiting great differences with those in the Ctrl group (P < 0.05). Moreover, no great difference was observed in laboratory indicators between patients in various groups (P > 0.05). After treatment, the Obs group exhibited better levels in all indicators. Furthermore, the incidence of ARs in the Obs group was lower and exhibited a sharp difference with that in the Ctrl group (P < 0.05).
Conclusion: SMTT had demonstrated good efficacy in patients with ALC, improving the DCR, enhancing the immune response of the body, and reducing the incidence of ARs, thereby promoting the disease outcome. Therefore, it was a treatment method worthy of promotion and application.
(© 2024. The Author(s).)

Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309. (PMID: 29861325)
Oncotarget. 2013 Aug;4(8):1117-8. (PMID: 23907631)
World J Gastroenterol. 2016 Apr 7;22(13):3547-57. (PMID: 27053846)
J Vasc Interv Radiol. 2022 Sep;33(9):1061-1065. (PMID: 36049841)
Biochim Biophys Acta. 2014 Dec;1846(2):439-45. (PMID: 25204853)
Expert Opin Investig Drugs. 2020 Feb;29(2):107-110. (PMID: 31986920)
J Cancer Res Ther. 2022 Apr;18(2):461-469. (PMID: 35645115)
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188638. (PMID: 34688805)
Curr Oncol Rep. 2022 Sep;24(9):1209-1218. (PMID: 35438389)
Front Immunol. 2021 Oct 04;12:765101. (PMID: 34675942)
Expert Rev Gastroenterol Hepatol. 2015 Jun;9(6):765-79. (PMID: 25827821)
Biochem Biophys Res Commun. 2023 Feb 12;644:85-94. (PMID: 36640667)
Crit Rev Oncog. 2020;25(1):31-46. (PMID: 32865909)
J Clin Invest. 2021 Oct 1;131(19):. (PMID: 34403373)
Semin Cancer Biol. 2011 Feb;21(1):59-69. (PMID: 21144900)
World J Gastroenterol. 2016 Jan 14;22(2):823-32. (PMID: 26811628)
Liver Int. 2022 Mar;42(3):488-491. (PMID: 35194931)
J Food Biochem. 2022 Oct;46(10):e14357. (PMID: 35945911)
N Z Med J. 2022 Dec 16;135(1567):91-104. (PMID: 36521088)
Cancer Lett. 2016 Sep 1;379(2):191-7. (PMID: 26213370)
Am J Gastroenterol. 2021 Nov 1;116(11):2197-2198. (PMID: 34279010)
Chin J Integr Med. 2016 Mar;22(3):163-7. (PMID: 26919996)
Curr Gene Ther. 2015;15(2):171-81. (PMID: 25537772)
Adv Sci (Weinh). 2022 May;9(15):e2103619. (PMID: 35343115)
Anal Cell Pathol (Amst). 2017;2017:5108653. (PMID: 28819584)
Nutrients. 2016 Mar 10;8(3):156. (PMID: 26978396)
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188621. (PMID: 34454983)
Cancer Biol Ther. 2016 Apr 2;17(4):457-66. (PMID: 26980196)
Expert Rev Anticancer Ther. 2017 Feb;17(2):119-127. (PMID: 27983883)
World J Gastroenterol. 2019 Jun 28;25(24):2977-2989. (PMID: 31293335)
Neoplasia. 2018 Jun;20(6):594-609. (PMID: 29747160)
Biosci Trends. 2021 Jul 6;15(3):155-160. (PMID: 34039818)
Bioengineered. 2021 Dec;12(2):9939-9948. (PMID: 34592904)
Biomed Pharmacother. 2019 Dec;120:109543. (PMID: 31655311)
Eur J Med Genet. 2021 Nov;64(11):104313. (PMID: 34418585)
Nature. 2019 Oct;574(7777):268-272. (PMID: 31578521)
Biomater Sci. 2021 Jul 13;9(14):4821-4842. (PMID: 34032223)
Int J Mol Sci. 2021 Jul 21;22(15):. (PMID: 34360566)
Int J Oncol. 2021 Dec;59(6):. (PMID: 34859259)
Cancer Commun (Lond). 2022 Nov;42(11):1112-1140. (PMID: 36069342)
Biomed Pharmacother. 2020 Aug;128:110284. (PMID: 32480224)

2020B0349 Jiangxi Province Traditional Chinese Medicine Science and Technology Plan Project; 20212BAB216064 Natural Science Foundation of Jiangxi Province

Keywords: Advanced liver cancer; Clinical efficacy; Disease control rate; Sorafenib; Targeted therapy; Transarterial chemoembolization

9ZOQ3TZI87 (Sorafenib)
0 (Antineoplastic Agents)
25X51I8RD4 (Niacinamide)
0 (Phenylurea Compounds)

Date Created: 20240411 Date Completed: 20240415 Latest Revision: 20240425

20240425

PMC11010384

10.1186/s12957-024-03364-y

38605359